Known targets — ChEMBL curated mechanism
fasrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmB1rpmB2rpmCrpmDrpmErpmFrpmG1rpmG2rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsR1rpsR2rpsSrpsTrpsZ
The experimentally established mechanism targets of Pyrazinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
| ▸ | MC4R | P32245 | 1/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.95 |
| ▸ | MC3R | P41968 | 1/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.68 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.68 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrazinamide SCHEMBL27524986 | 1.00 | ADORA3 (0.95) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL32667957 | 1.00 | ADORA3 (0.95) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL6162016 | 1.00 | ADORA3 (0.95) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL27474998 | 1.00 | ADORA3 (0.95) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL11616580 | 0.98 | ADORA3 (0.91) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazinamide SCHEMBL18364991 | 0.98 | — | — | |
| Pyrazinamide SCHEMBL18364989 | 0.98 | — | — | |
| Pyrazinamide SCHEMBL29518620 | 0.98 | — | — | |
| Pyrazinamide SCHEMBL29408106 | 0.98 | — | — | |
| Pyrazinamide SCHEMBL24102 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1585640-B | N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation | ASTRAZENECA AB | 2010-10-27 | — | — | CN | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| CN-1585640-A | N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation | ASTRAZENECA AB (SE) | 2005-02-23 | — | — | CN | claimed |
| EP-4370506-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023129667-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| CN-106478631-B | The preparation method of long-acting dipeptidyl peptidase-iv inhibitor, purposes and its intermediate | 四川科伦药物研究院有限公司 | 2019-04-05 | — | — | CN | disclosed |
| CN-106478631-A | The preparation method of long-acting dipeptidyl peptidase-iv inhibitor, purposes and its intermediate | 四川科伦药物研究院有限公司 | 2017-03-08 | — | — | CN | disclosed |
| CN-106103423-A | Chemical compound | 阿斯利康(瑞典)有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-104016980-A | Carboxamide compounds for treatment of metabolic disorders | RIGEL PHARMACEUTICALS INC | 2014-09-03 | — | — | CN | disclosed |
| CN-102099357-B | Carboxamide compounds for the treatment of metabolic disorders | RIGEL PHARMACEUTICALS INC | 2014-07-02 | — | — | CN | disclosed |
| CN-102099357-A | Carboxamide compounds for the treatment of metabolic disorders | RIGEL PHARMACEUTICALS INC | 2011-06-15 | — | — | CN | disclosed |
| CN-1585640-A | N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation | ASTRAZENECA AB (SE) | 2005-02-23 | — | — | CN | disclosed |
| EP-1456201-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | disclosed |
| CN-1147489-C | New bicyclo aminopyrazineone compound, its producing process and medical composition containing them | ɪά��ʵ���� | 2004-04-28 | — | — | CN | disclosed |
| EP-1368343-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003053957-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2002055518-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-18 | — | — | WO | disclosed |
| CN-1358723-A | Novel bicyclic amino-pyrazino ketone compound, its preparation method and medicinal composition having same | SEVEL LAB (FR) | 2002-07-17 | — | — | CN | disclosed |
| CN-1277198-A | New bicyclo aminopyrazineone compound, its producing process and medical composition containing them | ADIR (FR) | 2000-12-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | ADORA3 550/4885TSHR 1758/4885MC4R 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.